Redo Transcatheter Aortic Valve Replacement Appears to Be Safe and Effective

A matched-pair analysis demonstrates similar outcomes between redo and native-valve TAVR.

With the large growth in transcatheter aortic valve replacement (TAVR) procedures, it is likely that redo TAVR for failed prostheses will become increasingly necessary. In this industry-funded analysis of a U.S. TAVR registry, investigators compared the results of redo TAVR with a balloon-expandable valve (BEV) prosthesis with results of initial TAVR of native valve in matched patients.

Among 1320 propensity-matched pairs of patients (mean age, 78 years; 42% women; mean surgical risk, 8%), researchers found the following:

The median time to redo TAVR was 29 months.
Procedural complication rates were low (<1%) and not different between cohorts.
At 30 days, the rates of death (4%–5%) and stroke (2%) were similar, as were the rates of moderate or …

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)